Lupin Manufacturing Solutions (LMS), a subsidiary of the global pharmaceutical leader Lupin Limited, has announced a strategic expansion of its manufacturing facility in Dabhasa, India. This expansion is aimed at scaling its peptide building-blocks platform and enhancing its Contract Research, Development, and Manufacturing Organisation (CRDMO) capabilities.
The upgraded infrastructure will include a new block dedicated to enhancing existing CRDMO capabilities, supported by two additional specialized units for peptide manufacturing. These enhancements are designed to facilitate advanced development and flexible manufacturing, thereby supporting complex therapeutics and meeting the growing global demand for advanced pharmaceutical solutions.
Dr. Abdelaziz Toumi, Chief Executive Officer of Lupin Manufacturing Solutions, highlighted the importance of this expansion in the context of evolving pharmaceutical innovation. He stated, “As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical. This expansion underscores our commitment to building advanced, scalable capabilities that support complex development programs and reinforce our role in the global peptide ecosystem, enabling meaningful partnerships with innovators worldwide.”
The expansion is a response to the increasing complexity in global drug development, particularly in areas such as peptides and biologic Antibody-Drug Conjugates (ADCs). It reinforces LMS’s ability to consistently supply high-quality peptide building blocks, including protected amino acids.
Lupin Manufacturing Solutions, a wholly-owned subsidiary of Lupin Limited, is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and offers integrated solutions across drug substances, complex chemistry, drug products, and advanced modalities. With state-of-the-art facilities and a team of over 250 scientists, LMS supports biopharma innovators from early development to commercial scale.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).